Cell Source, Inc. (OTCBB: CLCS) is a biotechnology company focused on developing cell therapy treatments based on the management of immune tolerance. The company’s patented "Veto-Cell" technology represents a major breakthrough in immune system management - safe and selective “tolerizing” of immune response. Cell Source’s technology addresses one of the most fundamental challenges in human immunology: how to tune immune response so that it tolerates specific “desirable” foreign cells while continuing to attack all other potential threats. Cell Source is currently commercializing this groundbreaking innovation. Potential applications range from facilitating bone marrow and organ transplantation to effectively treating both blood cancers (e.g., Lymphoma) and non-malignant congenital diseases (e.g., Sickle Cell Anemia). SNNLive spoke with Itamar Shimrat, CEO of Cell Source, Inc. at The FireRock Conference 2014 in New York City, NY.
Mr. Shimrat begins with an overview of the company, “Essentially we’re in the field of immunology and regenerative medicine. Immunotherapy for cancer is called immuno-oncology and it’s a very hot area in biotech. The company is basically involved in three different products or areas." He continues, “The first one is if a patient needs a bone marrow transplant or a major organ transplant, they have two challenges: first of all they have to find a match donor, which is hard to do here and even harder to do in China, where they’ve had a one child per family law for many years, and secondly, even if they find a match donor their immune system still rejects the transplantation. So that has to be overcome using something called immune-suppression, which is typically very high levels of radiation and chemotherapy." He explains that due to these reasons, "it makes it very difficult to find donors and that the transplant itself has a very high mortality rate."
According to Mr. Shimrat, Cell Source offers technology and treatments that will help during the transplant and immune suppression stages, “With our proprietary technology, we can solve both of those problems. We can do what are called mismatched or only partially matched bone marrow transplants and organ transplants. We can reduce the immune suppression for a bone marrow transplant by 80 or 90%, which means the survival rate can go much much higher and we can do major organ transplants where after the transplant, the person leaves the hospital and their body will treat that kidney as if they were born with it, they don’t have to take anti-rejection every day anymore.” For more information, check out their website: www.Cell-Source.com
© 2017 Stock News Now
Supported by Superior Web Solutions